Russian Randomized Trial to Select Optimal Antibiotic Prophylaxis in Radical Cystectomy: Initial Results of MACS-TRIAL (NCT05392634)

Introduction. The key treatment for high-risk non-invasive bladder tumor or invasive urothelial cancer remains radical cystectomy (RCE), which provides the best survival rates. At the same time, the incidence of infectious complications in a number of studies reaches 33%, which in most cases causes repeated hospitalizations and disrupts the Enhanced Recovery After Surgery (ERAS) guidelines. Therefore, research into effective alternations of antibiotic prophylaxis remains relevant.

Materials and methods. The MACS trial is a Russian Phase 3 study with a prospective randomized set of participants to assess the incidence of infectious complications after RCE in the context of the ERAS guidelines (intermediate data snapshot after including 39% of the data). Detailed inclusion and exclusion criteria are published on ClinicalTrials. gov, ID – NCT05392634. The study has been approved by the Local Ethics Committee, No. 1/129 of April 28, 2022. Statistical data processing was performed with StatPlus:Mac LE.

Results and discussion. 36 patients were included in the study (39% of the expected sample). For the period from May 30, 2022 to February 01, 2023. A heterotopic Bricker reservoir was formed intracorporeally in 83.3% of cases (30/36), an orthotopic J-pouch reservoir was created in 13.8% of cases (5/36) and in 2.9% of cases (1/36) the urodereating stage was completed with ureteral clipping. No significant differences were revealed in urine bacterial contamination before surgery. However, in group A, the incidence of positive bacterial cultures, when the ureteric intubators were removed, was 2-fold higher than in the prolonged antibiotic therapy group: 7/14 cases (50.0%) and 3/12 cases (25.0%), respectively. In group B, the risk of complications in the prolonged antibiotic therapy group reduced by 47% within 30 days after RCE (HR 0.53 (95CI %: 0.21-1.32).

Conclusion. An intermediate data snapshot in MACS study revealed that RCE was associated with a high risk of early postoperative infectious complications. The prognostic significance of systemic inflammation indices as predictors of infectious complications subject to further evaluation in the remaining 61% of cases.

1. 1 Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (eds.) State of cancer care for population in Russia in 2021. Moscow; 2020 (In Russ.).

2. 2 Cai Q., Chen Y., Xin S., Zhang D., Pan J., Xie Z., et al. Temporal trends of bladder cancer incidence and mortality from 1990 to 2016 and projections to 2030. Transl Androl Urol. 2020;9(2):153–65. DOI: 10.21037/tau.2020.02.24

3. 3 Hautmann R.E., de Petriconi R.C., Volkmer B.G. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol. 2010;184(3):990–1235. DOI: 10.1016/j.juro.2010.05.037

4. 4 Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., Jarvis W.R. Guideline for prevention of surgical site infection, 1999. Am J Infect Control. 1999;27(2):97–132; quiz 133–4; discussion 96. PMID: 10196487

5. 5 Briko N.I., Bozhkova S.A., Brusina E.B., Zhedaeva M.V., Zubareva N.A., Zueva L.P., et al. Prevention of surgical site infections. Clinical guidelines. Nizhny Novgorod: Remedium Privolzhe; 2018. (In Russ.).

6. 6 Krasnow R.E., Mossanen M., Koo S., Kubiak D.W., Preston M.A., Chung B.I., et al. Prophylactic antibiotics and postoperative complications of radical cystectomy: a population based analysis in the United States. J Urol. 2017;198(2):297–304. DOI: 10.1016/j.juro.2017.02.3340

7. 7 Atduev V.A., Gasrataliev V.E., Ledyaev D.S., Shevelev I.S., Belsky V.A. Predictors for postoperative complications from radical cystectomy. P.A. Herzen Journal of Oncology. 2019;8(5):348–57 (In Russ.). DOI: 10-17116/onkolog20198051348

8. 8 Lawrentschuk N., Colombo R., Hakenberg O.W., Lerner S.P., Månsson W., Sagalowsky A., et al. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol. 2010;57(6):983–1001. DOI: 10.1016/j.eururo.2010.02.024

9. 9 Hollenbeck B.K., Miller D.C., Taub D., Dunn R.L., Khuri S.F., Henderson W.G., et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol. 2005;174(4 Pt 1):1231–7; discussion 1237. DOI: 10.1097/01.ju.0000173923.35338.99

10. 10 Nosov A.K., Reva S.A., Dzhalilov I.B., Petrov S.B. Radical cystectomy for bladder cancer: сomparison of early surgical complications during laparoscopic, open-access, and video-assisted surgery. Cancer Urology. 2015;11(3):71–8 (In Russ.). DOI: 10.17650/1726-9776-2015-11-3-71-78

11. 11 Studer U.E. Keys to successful orthotopic bladder substitution. Cham: Switzerland Springer International Publishing; 2015.

12. 12 Petrov S.B., Levkovsky N.S., Korol V.D., Parshin A.G. Radical cystectomy as the main treatment for muscle-invasive bladder cancer (indications, features of technique, prevention of complications). Practical oncology. 2003;4(4):225–30 (In Russ.).

13. 13 Perlin D.V., Alexandrov I.V., Zipunnikov V.P., Shmanev A.O. Laparoscopic radical cystectomy: key points. Cancer Urology. 2018;14(1):136–43 (In Russ.). DOI: 10.17650/1726-9776-2018-14-1-136-143

14. 14 Cerantola Y., Valerio M., Persson B., Jichlinski P., Ljungqvist O., Hubner M., et al. Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS(®)) society recommendations. Clin Nutr. 2013;32(6):879–87. DOI: 10.1016/j.clnu.2013.09.014

15. 15 Peerbocus M., Wang Z.J. Enhanced recovery after surgery and radical cystectomy: a systematic review and meta-analysis. Res Rep Urol. 2021;13:535–47. DOI: 10.2147/RRU.S307385

16. 16 Ahmed H., Davies F., Francis N., Farewell D., Butler C., Paranjothy S. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open. 2017;7(5):e015233. DOI: 10.1136/bmjopen-2016-015233